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other 4 patients developed either late AVB grade III (n= 3; day 9, day 14 and day 17
post TAVI) or progressive PR-interval lengthening in the presence of postinterventional
LBBB (n=1; day 5 post TAVI).
Conclusion: Therefore late occurrence of bradyarrhythmias should be recognized as
a significant contributor to postprocedural outcome after TAVI. Although this is a well
known phenomenon after surgical valve replacement, it is less recognized after TAVI
and should be considered in all patients after TAVI.
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Background: Transcatheter aortic valve implantation (TAVI) has evolved to a viable
tretment option for high-risk patients with severe aortic stenosis. While aspirine alone
is considered adequate after bioprosthetic surgical aortic valve replacement, dual
antiplatelet therapy (ASA & Clopidrogrel) is currently administrated for 6 months after
TAVI to prevent thrombus formation. However, the need for dual-antplatelet therapy
(DAT) and its duration is not supported by scientific evidence.
Methods: Since 2006 transfemoral TAVI was performed in 227 consecutive high-risk
patients (Edwards n=139;Medtronic Corevalve n= 98). We report a case series of 4
patients who received an Edwards bioprosthesis and showed a transient increase in
pressure gradients after termination of DAT.
Results: In one patient DAT was discontinued prematurely by the general practitioner
at 3 months. This patient showed an increase of heart-failure symptoms (NYHA I-II
Ç NYHA III) when he presented. This was accomplished by a significant increase of
Pmean from 12 to 43 mmHg. Subsequent TEE (fig.1) revealed thickness of the leaflet
tips with an impression of leaflet adhesion during opening. Resumption resulted in
normalisation of pressure gradients (fig.2) and a normal valve function with
unconspicious morphology. Similar findings were discovered in 3 additional cases.
Conclusion: A transient impairment of valve function was discovered in 4 TAVI patient
after termination of DAT. This raises questions regarding the duration of this medical
management and might potentially offer an explanation for the late strokes observed
in cohort of the PARTNER trial, namely formation of microthrombi on the non-
endothelialized surface of the bovine pericardial tissue leaflet.
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Background: Paravalvular aortic regurgitation (PVAR) frequently occurs after
transcatheter aortic valve implantation (TAVI) and moderate to severe paravalvular
incompetence is associated with poorer prognosis following TAVI. We have sought to
develop a novel low-profile sealing system that is compatible with contemporary TAVI
systems to eliminate PVAR.
Methods: A highly conformable TAVI sealing system has been developed and adapted
onto prototypes of current ballon-expandable and self-expanding TAVI systems. The
sealing system is activated without change in delivery steps for each system. The safety
and efficacy of the sealing system has been assessed in vitro and in vivo.
Results: When adapted onto balloon-expandable and self-expanding TAVI systems,
the sealing system did not increase device profile but produces a marginal increase in
deployment force (approx. 2N). Sealing efficacy was assessed in hard polycarbonate
models of aortic annuli modelled from patients who had suffered moderate or severe
paravalvular regurgitation following TAVI. In a 100% of the cases, the PAVR was
shown to be reduced to a none/trace level. Similar results were observed with the
sealing mechanism even when TAVI devices were suboptimally positioned above or
below the aortic annulus and also when placed in an oval-shaped annulus.
Snapshot of simulated aortogram comparing results for TAVI device implanted in a
simulated hard calcified annulus with and without the sealing technology
Percentage of dye leaked back into the ventricle calculated as a function of the dye
intensity
Conclusion: A low-profile, highly conformable sealing system can effectively seal
paravalvular regurgitation when adapted onto contemporary TAVI systems. Utilization
of specific seal technologies may effectively address paravalvular leaks following
TAVI.
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Background: Sizing of a transcatheter heart valve (THV) is often determined by two-
dimensional transesophageal echocardiographic (TEE) measurement of the aortic
annulus. However the aortic annulus is typically oval and may be better evaluated by
multi-detector computerised tomography (MDCT). The implications of an eccentric
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